Skip to main content
Fig. 5 | Cancer & Metabolism

Fig. 5

From: Beta-hydroxybutyrate (3-OHB) can influence the energetic phenotype of breast cancer cells, but does not impact their proliferation and the response to chemotherapy or radiation

Fig. 5

a The column-graphs show the cumulative IC50 of epirubicin, paclitaxel, and carboplatin in control cells (dark gray box) and cells cultured with 3 mM 3-OHB (light gray box). Per cell line, three to four each independent dose-response experiments with six replicate wells per experiment were calculated. b Representative dose-response curves obtained for BT-20 cells at 5% oxygen in chemotherapy sensitivity testing with the chemotherapeutic drugs (epirubicin, paclitaxel, carboplatin) which was used for the calculation of the IC50 (dashed line) (black box = control, white box = 3-OHB). c Same as b but for 21% oxygen. Curves summarize four independent experiments with six replicate wells per experiment

Back to article page

Cancer & Metabolism

ISSN: 2049-3002